Psilocybin Is at the FDA's Door. Recovery Rooms Need to Talk About It Before It Walks In.

Picture someone three years into recovery who has also spent those three years fighting a depression that two antidepressants never touched. Next year, their psychiatrist may be able to offer them a supervised dose of psilocybin, the active compound in mushrooms. They will have to decide what that means for their sobriety date, and so will the people in their home group. On November 9, Compass Pathways said it had completed its FDA application for COMP360 psilocybin for treatment-resistant depression, and that question stopped being hypothetical.

A medicine given by a clinician on a schedule is not the same act as using, and recovery communities that refuse to say so out loud will lose the people who need both.

Start with what the evidence actually shows, because the hype will not. In Compass’s two phase 3 trials, a single 25-milligram dose lowered depression scores by 3.6 points more than placebo at six weeks in one study of 258 people, and 3.8 points more than a tiny 1-milligram dose in a second study of 581. On the scale used, that is a real but modest difference, not a miracle. Serious side effects showed up in about 5 to 6 percent of people in both the real and comparison arms, and suicidal thoughts in under 1 percent. Even if the FDA approves it, psilocybin is Schedule I, so the DEA and individual states must reschedule it before anyone can prescribe it. Compass is aiming for the first half of 2027. That is the gate.

The addiction evidence is earlier still. A small University of Alabama at Birmingham trial published in May in JAMA Network Open gave 40 adults with cocaine use disorder either psilocybin or an active placebo alongside the same therapy; 6 of 20 in the psilocybin group stayed fully abstinent through six months, versus none in the placebo group. Most participants were Black and low-income, people trials usually miss. The authors call it hypothesis-generating: one site, small, and the lead author was also the therapist. That is a reason to run the bigger trial, not to buy mushrooms.

The psychology is where recovery communities get stuck. If you got sober by drawing a hard line around every mind-altering substance, a drug that works partly by altering your mind can feel like a trapdoor. That fear is worth respecting. But many people in recovery already take buprenorphine, methadone, or antidepressants, and most rooms have learned, sometimes slowly, that medicine prescribed for an illness is not a relapse.

For clinicians, the move this month: if you treat patients in recovery, start asking now whether psychedelic therapy would be a fit or a risk for them, and write down how your practice will handle a patient who asks in 2027. Follow psychedelics coverage and science and medicine here.

You get to decide what counts for your recovery. Decide it with your doctor and your people, before a sales rep or a headline decides it for you.